Hybridoma Platform Using Multi-Site Immunization for Difficult Targets
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing hybridoma technology is limited in generating increased numbers of antigen-specific antibodies and improving monoclonal antibody production, particularly for challenging targets such as multipass transmembrane proteins like GPCRs, ion pumps, and ion channels.
Innovation Solution
A method involving outbred animals injected at multiple sites with antigen, using multiple adjuvants, and harvesting B cells from draining lymph nodes to form hybridomas, followed by enrichment and screening for antigen specificity, utilizing fusion partners that express both surface and secreted IgG.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If traditional hybridoma methods are used, then the process is simple and well-established, but the number of antigen-specific antibodies produced is limited
Solution Approach 1:
The immunization protocol is segmented into multiple independent injection sites (e.g., foot pads, ear pins, tail base) rather than a single site. Each site acts as an independent immunization zone that drains to separate lymph nodes, effectively creating multiple parallel antibody production pathways from a single animal.
Solution Approach 2:
The approach transitions from single-site to multi-site immunization, adding a spatial dimension to the immunization protocol. This dimensional expansion allows simultaneous stimulation of multiple lymph node populations, dramatically increasing the diversity and quantity of antigen-specific B cells available for hybridoma formation.
2Productivity
If multiple adjuvants and injection sites are used, then antibody production increases significantly, but the complexity of the protocol increases
Solution Approach 1:
The protocol uses multiple adjuvants (Complete Freund's Adjuvant, Incomplete Freund's Adjuvant, and aluminum phosphate) that serve universal functions of enhancing immune response. Each adjuvant can be applied at different injection sites, providing a universal strategy that works across multiple anatomical locations and antigen types.
Solution Approach 2:
The protocol performs preliminary actions by establishing a robust multi-site immunization regimen before hybridoma formation. This preliminary phase ensures high titers of antigen-specific B cells are present in the spleen and lymph nodes, making the subsequent hybridoma formation step highly efficient and reducing the need for extensive screening.
3Quantity of substance
If traditional single-site immunization is used, then the protocol is simple, but the number of antigen-specific B cells is limited
Solution Approach 1:
The immunization protocol is segmented into multiple independent injection sites (e.g., foot pads, ear pins, tail base) rather than a single site. Each site acts as an independent immunization zone that drains to separate lymph nodes, effectively creating multiple parallel antibody production pathways from a single animal.
Solution Approach 2:
The approach transitions from single-site to multi-site immunization, adding a spatial dimension to the immunization protocol. This dimensional expansion allows simultaneous stimulation of multiple lymph node populations, dramatically increasing the diversity and quantity of antigen-specific B cells available for hybridoma formation.
Data Source
AI summary
The instant technology generally relates to improved methods for producing antibodies, antibody libraries, hybridomas, hybridoma libraries, etc. For example, these methods increase the number of antigen-specific B cells produced, increase the number of hybridomas, and/or increase the number of monoclonal antibodies that can be made in a given production cycle.